ResultsIQ

ResultsIQ › Latest results › Sai Life Sciences Limited

Sai Life Sciences Limited Q2 FY27 earnings call summary

NSE: SAILIFE · BSE: 544306

Earnings call of 6 Nov 2026, summarised by AI from the filing.

Q2 FY27 revenue grew 23% with EBITDA margin at 28%, and management expects H2 FY27 to be stronger than H1.

Key takeaways

  1. Q2 revenue Revenue grew 23% year-on-year in Q2 FY27, with CDMO up 20% and CRO up 28%; EBITDA margin was 28%.
  2. Capacity slip Commissioning of the additional 225 KL capacity moved to early Q3 FY28 from the earlier timeline, without affecting FY28 revenue commitments.
  3. Integrated deals A second large pharma relationship was converted into an integrated strategic engagement, after the first one commenced operations.
  4. Cost pressure The Middle East situation raised costs of certain chemicals and solvents, with recovery from customers being pursued.

Original filing on BSE

Sai Life Sciences Limited Q2 FY27 results

As filed: Revenue ₹659 cr (+23% year on year), EBITDA ₹186 cr (+28% year on year), PAT ₹98.3 cr (+17% year on year), EBITDA margin 28.3% (+111 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹554 cr (+12% year on year), EBITDA ₹148 cr (+22% year on year), PAT ₹73.3 cr (+22% year on year), EBITDA margin 26.7% (+231 bps). Score 64 of 100, In line with trend. EBITDA margin rose 231 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 8% from last quarter. Share price after the results: +12.1% in 29 days (Nifty 500: −2.0%).
  • Q4 FY26: Revenue ₹602 cr (+4% year on year), EBITDA ₹177 cr (+12% year on year), PAT ₹104 cr (+18% year on year), EBITDA margin 29.3% (+225 bps). Score 53 of 100, In line with trend. EBITDA margin rose 225 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +9.5% in 29 days (Nifty 500: −0.1%).
  • Q3 FY26: Revenue ₹556 cr (+26% year on year), EBITDA ₹188 cr (+57% year on year), PAT ₹100 cr (+86% year on year), EBITDA margin 33.8% (+649 bps). Score 92 of 100, Above trend. EBITDA margin rose 649 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +27.9% in 29 days (Nifty 500: −4.0%).
  • Q2 FY26: Revenue ₹527 cr, EBITDA ₹140 cr, PAT ₹83.0 cr, EBITDA margin 26.6%. Not scored. No result for the same quarter last year. Share price after the results: −5.0% in 29 days (Nifty 500: +1.4%).
  • Q1 FY26: Revenue ₹483 cr, EBITDA ₹113 cr, PAT ₹58.0 cr, EBITDA margin 23.4%. Not scored. No result for the same quarter last year. Share price after the results: +8.7% in 29 days (Nifty 500: +0.6%).
  • Q4 FY25: Revenue ₹567 cr, EBITDA ₹153 cr, PAT ₹90.0 cr, EBITDA margin 27.0%. Not scored. No result for the same quarter last year. Share price after the results: +6.1% in 30 days (Nifty 500: +2.5%).
  • Q3 FY25: Revenue ₹429 cr, EBITDA ₹112 cr, PAT ₹51.0 cr, EBITDA margin 26.1%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Sai Life Sciences Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.